Nuchido TIME+ NAD Supplement (30-Day Supply)

Product Overview

Nuchido TIME+ is a scientifically formulated NAD+ restoration supplement developed by Nuchido Ltd, a University of Edinburgh spinout founded on research into the systems biology of cellular ageing and NAD+ metabolism. NAD+ is a coenzyme present in every living cell, functioning as the central electron carrier in mitochondrial oxidative phosphorylation (the electron transport chain), as an obligatory substrate for sirtuins (SIRT1–SIRT7) — the class of NAD+-dependent deacylase enzymes that regulate gene expression, DNA damage repair, mitochondrial biogenesis, and metabolic homeostasis — and as the substrate for PARP enzymes (poly ADP-ribose polymerases) that detect and repair DNA strand breaks. Age-related NAD+ decline, documented at 25–50% reduction between ages 20 and 70 in multiple human tissue studies, compromises all three of these fundamental cellular maintenance processes.

Unlike single-ingredient NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) supplements that supply only one NAD+ biosynthesis precursor, Nuchido TIME+ addresses the NAD+ pathway at multiple points: precursor supplementation to increase NAD+ biosynthesis input; inhibition of ACMSD (alpha-amino-beta-carboxymuconate-semialdehyde decarboxylase), which diverts tryptophan-derived intermediates away from NAD+ synthesis and towards non-productive catabolism; and suppression of CD38, a key NAD+-consuming ectoenzyme whose age-associated upregulation is a primary driver of NAD+ depletion in tissues. This multi-pathway approach is designed to elevate NAD+ more effectively and sustainably than precursor supplementation alone by simultaneously increasing synthesis input and reducing degradation output. The 30-Day Supply (60 capsules at 2 capsules per day) provides an initial course for evaluating individual response before committing to the 90-Day flagship subscription.

Specifications

Key Applications

• Cellular energy support in age-related NAD+ decline: Adults aged 35 and above experiencing fatigue, reduced exercise tolerance, or diminished cognitive function associated with mitochondrial energetic decline — for whom restoration of NAD+ to younger-adult levels may support subjective energy and metabolic function.
• Sirtuin pathway activation for healthy ageing: SIRT1 activation requires NAD+ as an obligatory substrate; SIRT1 regulates PGC-1α (mitochondrial biogenesis), FOXO3 (antioxidant defence, apoptosis regulation), and NF-κB (inflammatory gene expression). Supporting sirtuin function through NAD+ restoration is a mechanistically grounded approach to healthy ageing support.
• Mitochondrial function maintenance: NAD+ is essential for Complex I and Complex III of the mitochondrial electron transport chain; NAD+ depletion impairs ATP synthesis efficiency, reducing the energy available for cellular repair, immune function, and metabolic regulation. Indicated for individuals with occupational, physical, or chronological demands on cellular energy systems.
• 30-day entry course before 90-day commitment: The 30-day supply (60 capsules) allows clinical assessment of individual tolerance and subjective response to NAD+ supplementation before transitioning to the cost-effective 90-day supply. Recommended as an initial trial for patients new to NAD+ pathway supplementation, particularly in Singapore's wellness medicine and longevity clinic context.
• Corporate and institutional wellness programmes: Supplied to Singapore corporate wellness programmes, executive health screening clinics, and longevity medicine practices as a premium supplement component for employees and patients in high-cognitive-demand roles.

Frequently Asked Questions

Q: How does Nuchido TIME+ differ from single-ingredient NMN or NR supplements?
A: Standard NMN or NR supplements provide a single NAD+ precursor, increasing biosynthesis input at one point in the Salvage pathway. Nuchido TIME+ addresses multiple regulatory nodes simultaneously: precursor supply, ACMSD pathway inhibition (redirecting tryptophan-derived intermediates towards NAD+ synthesis), and CD38 suppression (reducing NAD+ degradation). Age-related NAD+ depletion is driven both by declining synthesis and increasing degradation; addressing only the precursor side leaves the degradation driver unresolved. The theoretical advantage of multi-pathway intervention is a higher, more sustained NAD+ elevation compared to precursor-only supplementation.

Q: What is the scientific basis for Nuchido TIME+?
A: Nuchido Ltd was founded as a spinout of the University of Edinburgh, with scientific advisory input from researchers specialising in the systems biology of ageing and NAD+ metabolism. The company has conducted internal research on the multi-pathway NAD+ restoration approach. Peer-reviewed clinical data specifically on Nuchido TIME+ as a commercial product is limited in publicly available literature as of early 2026; the mechanistic rationale draws on published research on the roles of CD38 upregulation and ACMSD pathway competition in age-related NAD+ decline (Camacho-Pereira et al., Cell Metabolism 2016 on CD38; Rajman et al., Cell Metabolism 2018 on NAD+ and ageing). Consumers and clinicians seeking independent clinical trial data on this specific formulation should contact Nuchido Ltd directly for any available unpublished study data.

Q: Is Nuchido TIME+ registered as a health supplement in Singapore?
A: Nuchido TIME+ is classified as a health supplement under the Singapore Health Products Act (Cap. 122D) and the Health Products (Health Supplements) Regulations administered by the Health Sciences Authority (HSA). Health supplements in Singapore do not require pre-market approval but must be notified to HSA and comply with ingredient restrictions, labelling requirements, and permitted health claims per the ASEAN Regulatory Guidelines for Traditional Medicines and Health Supplements. Permitted claims relate to general wellbeing (e.g., "supports cellular energy") rather than disease treatment or prevention. EMIS sources and distributes Nuchido TIME+ through compliant channels in Singapore.

Q: What is the difference between the 30-Day and 90-Day supply?
A: The 30-Day Supply (60 capsules) provides a one-month initial course at 2 capsules daily — intended for individuals trialling NAD+ supplementation for the first time or assessing individual response and tolerance. The 90-Day Supply (180 capsules) is the flagship format, providing a sustained 3-month course which aligns with the timeframe for measurable changes in mitochondrial biogenesis and sirtuin-dependent cellular remodelling processes. For ongoing supplementation, the 90-day format offers improved cost-per-day and reduces interruptions in the supplementation schedule.

Q: Are there any contraindications or interactions to be aware of in the Singapore clinical context?
A: As a health supplement, Nuchido TIME+ has not undergone the clinical trial programme required for pharmaceutical registration. Individuals on prescription medications — particularly those modulating PARP, sirtuin, or mTOR pathways (e.g., cancer therapies, immunosuppressants) — should consult their physician before commencing NAD+ supplementation. Nicotinamide-based compounds are generally well-tolerated; transient flushing is more commonly associated with nicotinic acid (niacin) than with NMN or NR at standard doses. Pregnant or breastfeeding individuals should avoid NAD+ supplements in the absence of specific safety data. Advice should be sought from a Singapore-registered pharmacist or physician for personalised assessment.

Available in Singapore from EMIS (Essential Medical International Supplies Pte Ltd), 30-Day Supply (60 capsules). For clinic stock, corporate wellness, or B2B procurement enquiries, contact our team at emis.asia.